Total Payments
$1.3M
2024 Payments
$211,313
Companies
44
Transactions
1,092
Medicare Patients
7,696
Medicare Billing
$4.4M
Payment Breakdown by Category
Other$646,670 (48.8%)
Consulting$325,997 (24.6%)
Research$227,713 (17.2%)
Travel$108,805 (8.2%)
Food & Beverage$16,968 (1.3%)
Education$76.44 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $646,670 | 236 | 48.8% |
| Consulting Fee | $325,997 | 173 | 24.6% |
| Unspecified | $227,713 | 29 | 17.2% |
| Travel and Lodging | $108,805 | 304 | 8.2% |
| Food and Beverage | $16,968 | 341 | 1.3% |
| Education | $76.44 | 9 | 0.0% |
Payments by Type
General
$1.1M
1,063 transactions
Research
$227,713
29 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $350,518 | 339 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $211,893 | 220 | $0 (2024) |
| Amgen Inc. | $196,031 | 132 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $151,623 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $98,265 | 84 | $0 (2024) |
| Celgene Corporation | $74,345 | 14 | $0 (2022) |
| Merck Sharp & Dohme LLC | $56,333 | 50 | $0 (2024) |
| EMD Serono, Inc. | $44,633 | 38 | $0 (2023) |
| GENZYME CORPORATION | $26,098 | 23 | $0 (2024) |
| PFIZER INC. | $23,195 | 30 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $211,313 | 245 | Janssen Biotech, Inc. ($70,627) |
| 2023 | $262,193 | 241 | Janssen Biotech, Inc. ($81,642) |
| 2022 | $210,495 | 161 | Janssen Biotech, Inc. ($101,612) |
| 2021 | $153,208 | 102 | Amgen Inc. ($49,993) |
| 2020 | $103,914 | 86 | E.R. Squibb & Sons, L.L.C. ($30,176) |
| 2019 | $244,629 | 96 | Takeda Pharmaceuticals U.S.A., Inc. ($149,278) |
| 2018 | $41,453 | 77 | E.R. Squibb & Sons, L.L.C. ($25,888) |
| 2017 | $99,024 | 84 | Celgene Corporation ($57,790) |
All Payment Transactions
1,092 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,335.00 | General |
| 12/20/2024 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $2,271.50 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $735.74 | General |
| 12/19/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $0.54 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $6.44 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $494.00 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $850.63 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $138.60 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| 12/02/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| 12/02/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $30.64 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $735.74 | General |
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Amgen Inc. | — | Travel and Lodging | In-kind items and services | $1,056.54 | General |
| 11/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $124.13 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $111.74 | General |
| 11/19/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $1.99 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ALTA-1L Ph3 Brigatinib vs Crizotinib | Takeda Pharmaceuticals U.S.A., Inc. | $149,278 | 17 |
| ABI-007-ST-001 | Celgene Corporation | $54,515 | 1 |
| A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv non-small cell lung cancer or nab-paclitaxel in metastastic breast cancer (ABI-007-ST-001) | Celgene Corporation | $12,810 | 2 |
| MAIC between Sotorasib and Adagrasib | Amgen Inc. | $5,655 | 1 |
| AX-CL-NSCLC-Alliance-006861 | Celgene Corporation | $1,905 | 1 |
| ABI-007-NSCL-003 | Celgene Corporation | $1,370 | 1 |
| ABI-007-NSCL-003 - A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in su | Celgene Corporation | $1,229 | 1 |
| ABI-007-ST-001 - A phase 1, open-label, multicenter, safety study of nivolumab (bms-936558) in combination with nab-pacitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage iiib/iv | Celgene Corporation | $442.00 | 1 |
| A PHASE 2 STUDY OF LY2606368 IN PATIENTS WITH EXTENSIVE STAGE DISEASE SMALL CELL LUNG CANCER | Eli Lilly and Company | $179.40 | 1 |
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC) (ABI-007-NSCL-003) | Celgene Corporation | $136.50 | 1 |
| Real world US NSCLC standard of care | Amgen Inc. | $120.36 | 1 |
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $72.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 475 | 1,146 | $218,021 | $45,455 |
| 2022 | 26 | 1,442 | 4,388 | $924,307 | $155,636 |
| 2021 | 48 | 2,948 | 70,066 | $6.1M | $1.6M |
| 2020 | 52 | 2,831 | 118,419 | $10.3M | $2.6M |
Total Patients
7,696
Total Services
194,019
Medicare Billing
$4.4M
Procedure Codes
141
All Medicare Procedures & Services
141 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 149 | $51,815 | $12,076 | 23.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 90 | $30,861 | $8,400 | 27.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 26 | 54 | $36,358 | $5,058 | 13.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $16,745 | $3,952 | 23.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 26 | 26 | $19,028 | $3,605 | 18.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 26 | $14,048 | $3,075 | 21.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 46 | 56 | $12,908 | $3,008 | 23.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 35 | $9,390 | $2,211 | 23.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 19 | $5,776 | $891.67 | 15.4% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 47 | 116 | $4,060 | $882.76 | 21.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 17 | 39 | $5,928 | $817.90 | 13.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 37 | 70 | $4,340 | $724.50 | 16.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 45 | $4,185 | $477.45 | 11.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 11 | 21 | $2,205 | $239.97 | 10.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 18 | 374 | $374.00 | $36.11 | 9.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 222 | 503 | $164,981 | $41,599 | 25.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 45 | 155 | $24,800 | $24,721 | 99.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 47 | 150 | $102,214 | $15,014 | 14.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 71 | 85 | $60,183 | $13,167 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 59 | 90 | $48,184 | $10,710 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 165 | 205 | $43,515 | $10,341 | 23.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 13 | 60 | $236,280 | $8,879 | 3.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 75 | $27,153 | $6,114 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 37 | 37 | $29,819 | $5,450 | 18.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 231 | 531 | $18,585 | $4,091 | 22.0% |
About Dr. David Waterhouse, MD
Dr. David Waterhouse, MD is a Hematology & Oncology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1578557864.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Waterhouse, MD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $211,313 received in 2024. These payments were reported across 1,092 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($646,670).
As a Medicare-enrolled provider, Waterhouse has provided services to 7,696 Medicare beneficiaries, totaling 194,019 services with total Medicare billing of $4.4M. Data is available for 4 years (2020–2023), covering 141 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Cincinnati, OH
- Active Since 09/01/2005
- Last Updated 04/14/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1578557864
Products in Payments
- ERLEADA (Drug) $174,774
- OPDIVO (Biological) $155,540
- Alunbrig (Drug) $149,278
- RYBREVANT (Drug) $145,216
- LUMAKRAS (Drug) $126,285
- LYNPARZA (Drug) $80,246
- Abraxane (Drug) $72,407
- Erleada (Drug) $36,229
- TEPMETKO (Drug) $29,798
- KEYTRUDA (Biological) $28,010
- LYNPARZA (Biological) $22,384
- Stimufend (Biological) $16,317
- ZEPZELCA (Drug) $12,793
- TAGRISSO (Drug) $9,224
- Bavencio (Drug) $6,900
- Tepmetko (Drug) $5,520
- IMFINZI (Biological) $5,514
- ZYTIGA (Drug) $4,407
- Lenvima (Drug) $2,970
- TABRECTA (Drug) $2,657
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cincinnati
Dr. Elyse Lower, Md, MD
Hematology & Oncology — Payments: $386,700
Hematology & Oncology $386,700
Dr. Alexander Starodub, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $254,325
Hematology & Oncology $254,325
Dr. James Essell, Md, MD
Hematology & Oncology — Payments: $223,019
Hematology & Oncology $223,019
Davendra Sohal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $124,378
Hematology & Oncology $124,378
Dr. Edward Faber, D.o., M.s, D.O., M.S
Hematology & Oncology — Payments: $116,895
Hematology & Oncology $116,895
Dr. Soumit Basu, M.d. Ph.d, M.D. PH.D
Hematology & Oncology — Payments: $114,168
Hematology & Oncology $114,168